title: Effects on resting cerebral blood flow and functional connectivity induced by metoclopramide: a perfusion MRI study in healthy volunteers.
abstract: BACKGROUND AND PURPOSE The substituted benzamide, metoclopramide, is a dopamine receptor antagonist and is widely prescribed in the symptomatic treatment of nausea and vomiting, although it can cause adverse motor and non-motor side effects. The effects of metoclopramide on brain metabolism have not been investigated to date. EXPERIMENTAL APPROACH To determine the effects of metoclopramide on brain function, cerebral perfusion changes after a single oral dose were assessed in healthy volunteers using magnetic resonance imaging (MRI) techniques. Arterial spin labelling (ASL) perfusion MRI was used to measure cerebral blood flow before and after metoclopramide. Blood haemodynamics in the vertebral and internal carotid arteries were evaluated using phase-contrast MRI. KEY RESULTS Metoclopramide altered haemodynamics in the carotid arteries and the cerebral perfusion. Perfusion increased bilaterally in the putamen, consistent with antagonism of dopamine D(2) receptors by metoclopramide and possibly related to its motor side effects. In contrast, reduced perfusion was observed in the insular cortices and anterior temporal lobes. In addition, functional connectivity between the insular cortex and the dorsolateral prefrontal cortex was decreased. These cortical changes affecting neural circuits between high-order association areas may underlie certain neuropsychiatric conditions occasionally reported after metoclopramide administration. CONCLUSIONS AND IMPLICATIONS The present results show the sensitivity of ASL to detect small changes in regional blood flow, closely related to brain function, after a single pharmacological challenge, highlighting the potential of this technique for human pharmacological studies.
authors.affiliation: Functional Neuroimaging Laboratory, Division of Neuroscience, Center for Applied Medical Research, University of Navarra, Pamplona, Spain. mfseara@unav.es
authors.forename: María A
authors.initials: MA
authors.lastname: Fernández-Seara
authors.forename: Maite
authors.initials: M
authors.lastname: Aznárez-Sanado
authors.forename: Elisa
authors.initials: E
authors.lastname: Mengual
authors.forename: Jaione
authors.initials: J
authors.lastname: Irigoyen
authors.forename: Franz
authors.initials: F
authors.lastname: Heukamp
authors.forename: María A
authors.initials: MA
authors.lastname: Pastor
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001158:Arteries; D001921:Brain / Q000098:blood supply* / Q000187:drug effects* / Q000502:physiology; D002560:Cerebrovascular Circulation / Q000187:drug effects* / Q000502:physiology; D035061:Control Groups; D018492:Dopamine Antagonists / Q000009:adverse effects / Q000494:pharmacology*; D004334:Drug Administration Schedule; D005260:Female; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D018810:Magnetic Resonance Angiography; D008297:Male; D008787:Metoclopramide / Q000009:adverse effects / Q000494:pharmacology*; D010919:Placebos; D015203:Reproducibility of Results; D012146:Rest; D016037:Single-Blind Method; D013113:Spin Labels; D055815:Young Adult
chemical_list: D018492:Dopamine Antagonists; D010919:Placebos; D013113:Spin Labels; D008787:Metoclopramide